TORONTO, March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that Mr. Anthony Bihl has been appointed to the Company's Board of Directors.
"As the former CEO of Siemens Medical Solutions Diagnostics, a combination of the former Bayer Diagnostics and Diagnostic Products Corporation, Mr. Bihl will be a valuable addition to our Board," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Mr. Bihl is a 25 year veteran in the field of diagnostics and is well-suited to advise Spectral on our global commercialization strategy of the EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin."
Mr. Bihl has more than 25 years of experience with diagnostic products, having held leadership roles in global healthcare businesses, including a broad base of operational and executive positions in large and medium multinational healthcare firms. Before his role as CEO of Siemens Medical Solutions Diagnostics, Mr. Bihl served in senior leadership roles at Bayer Healthcare Diagnostics, having held the roles of Senior VP of Finance and Administration and President, responsible for all aspects of this worldwide business Division. Prior to his tenure at Bayer, Mr. Bihl gained extensive operational experience through more than 20 years at E.I. DuPont Inc. His final role at DuPont was as Plant Manager for medical instrument manufacturing.
Mr. Bihl received a Bachelor's Degree in Business Administration from Pennsylvania State University, and is a member of the Board of Directors for Adnavance Technologies Inc.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral's lead product is its EAA(TM) Endotoxin
Activity Assay, the only FDA approved diagnostic for the measurement of
endotoxin. Spectral technologies provide accurate and timely information to
clinicians enabling the early initiation of app
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved